Literature DB >> 21523847

Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy.

Giovanni Santone1, Cesario Bellantuono, Paola Rucci, Angelo Picardi, Antonio Preti, Giovanni de Girolamo.   

Abstract

PURPOSE: The present study investigated: (i) the rate of prescription of antipsychotic (AP) polypharmacy (APP) in a large, representative sample of psychiatric inpatients; and (ii) the relationship between APP prescription and the characteristics of patients and facilities.
METHODS: The sample included 1022 psychiatric patients scheduled to be discharged from acute inpatient facilities with drug therapies including AP. Demographic and clinical data were obtained from the treating physician or retrieved from patients' records through a standardized Patient Form. Patients were administered the 24-item Brief Psychiatric Rating Scale. Three indicators were used to describe the process of care in the facilities: a Restrictiveness score, a Standardization score, and a Treatment score. A multilevel mixed-effect logistic regression was used to predict APP using patient and facility as the variables.
RESULTS: APP was prescribed to 333 (32.5%) patients, the most common patterns being a first-generation and a second-generation AP (n = 178, 17.6%) or of two first-generation APs (n = 80, 7.8%). Patients with a diagnosis of schizophrenia and poorer insight into illness at admission were significantly more likely to receive APP. The availability of more complex therapeutic interventions in the facility was also associated with APP.
CONCLUSIONS: In our nationwide sample of psychiatric inpatients, APP was frequently prescribed to treat the more severe patients. However, it was also associated with process of care characteristics such as delivery of more complex therapeutic interventions, and was therefore not used only to control patient behavior.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21523847     DOI: 10.1002/pds.2083

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

1.  Quality of care indicators for schizophrenia: determinants of observed variations among Italian Departments of Mental Health. Results from the ETAS DSM study.

Authors:  G Fantini; G Tibaldi; P Rucci; D Gibertoni; M Vezzoli; L Cifarelli; R Tiraferri; C Munizza
Journal:  Epidemiol Psychiatr Sci       Date:  2016-03-28       Impact factor: 6.892

Review 2.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

3.  Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.

Authors:  Maxine D Fisher; Kathleen Reilly; Keith Isenberg; Kathleen F Villa
Journal:  BMC Psychiatry       Date:  2014-11-30       Impact factor: 3.630

4.  Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.

Authors:  Sara S McMillan; Sara Jacobs; Louise Wilson; Theo Theodoros; Gail Robinson; Claire Anderson; Gabor Mihala; Amanda J Wheeler
Journal:  BMC Psychiatry       Date:  2017-04-13       Impact factor: 3.630

5.  Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis.

Authors:  Andrea Marcellusi; Gianluca Fabiano; Raffaella Viti; Pier Cesare Francesa Morel; Giuseppe Nicolò; Alberto Siracusano; Francesco Saverio Mennini
Journal:  BMJ Open       Date:  2018-02-08       Impact factor: 2.692

6.  Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study.

Authors:  Felice Iasevoli; Elisabetta F Buonaguro; Massimo Marconi; Emanuela Di Giovambattista; Maria Paola Rapagnani; Domenico De Berardis; Giovanni Martinotti; Monica Mazza; Raffaele Balletta; Nicola Serroni; Massimo Di Giannantonio; Andrea de Bartolomeis; Alessandro Valchera
Journal:  ISRN Pharmacol       Date:  2014-01-27

7.  Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy.

Authors:  Hee-Yun Kim; Hee-Won Lee; Seung-Ho Jung; Min-Hee Kang; Jae-Nam Bae; Jeong-Seop Lee; Chul-Eung Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-08-12       Impact factor: 2.582

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.